Guillaume Ploussard1, Shahrokh F Shariat2, Alice Dragomir3, Luis A Kluth4, Evanguelos Xylinas5, Alexandra Masson-Lecomte6, Malte Rieken7, Michael Rink8, Kazumasa Matsumoto9, Eiji Kikuchi10, Tobias Klatte11, Stephen A Boorjian12, Yair Lotan13, Florian Roghmann14, Adrian S Fairey15, Yves Fradet16, Peter C Black17, Ricardo Rendon18, Jonathan Izawa19, Wassim Kassouf20. 1. Department of Surgery, Division of Urology, McGill University, Montreal, QC, Canada; Department of Urology, Saint-Louis Hospital, Assistance Publique Hôpitaux de Paris, Paris, France. 2. Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA; Department of Urology, Medical University of Vienna, Vienna, Austria. 3. Department of Surgery, Division of Urology, McGill University, Montreal, QC, Canada. 4. Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA; Department of Urology, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany. 5. Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA; Department of Urology, Cochin Hospital, Assistance Publique Hôpitaux de Paris, Paris Descartes University, Paris, France. 6. Department of Urology, Henri Mondor Hospital, Assistance Publique Hôpitaux de Paris, Paris Est Créteil University, Créteil, France. 7. Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA; Department of Urology, University Hospital Basel, Basel, Switzerland. 8. Department of Urology, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany. 9. Department of Urology, Kitasato University School of Medicine, Minami-ku, Sagamihara, Kanagawa, Japan. 10. Department of Urology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan. 11. Department of Urology, Medical University of Vienna, Vienna, Austria. 12. Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, MN, USA. 13. Department of Urology, University of Texas Southwestern Medical Center, Dallas, Dallas, TX, USA. 14. Department of Urology, Ruhr-University Bochum, Marienhospital, Herne, Germany. 15. Department of Surgery, University of Alberta, Edmonton, AB, Canada. 16. Department of Surgery, Laval University, Quebec, QC, Canada. 17. Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. 18. Department of Surgery, Dalhousie University, Halifax, NS, Canada. 19. Department of Surgery, Western University, London, ON, Canada. 20. Department of Surgery, Division of Urology, McGill University, Montreal, QC, Canada. Electronic address: wassim.kassouf@muhc.mcgill.ca.
Abstract
BACKGROUND: Standard survival statistics do not take into consideration the changes in the weight of individual variables at subsequent times after the diagnosis and initial treatment of bladder cancer. OBJECTIVE: To assess the changes in 5-yr conditional survival (CS) rates after radical cystectomy for bladder cancer and to determine how well-established prognostic factors evolve over time. DESIGN, SETTING, AND PARTICIPANTS: We analyzed data from 8141 patients treated with radical cystectomy at 15 international academic centers between 1979 and 2012. INTERVENTIONS: Radical cystectomy and pelvic lymph node dissection. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Conditional cancer-specific survival (CSS) and overall survival (OS) estimates were calculated using the Kaplan-Meier method. The multivariable Cox regression model was used to calculate proportional hazard ratios for the prediction of mortality after stratification by clinical characteristics (age, perioperative chemotherapy status) and pathologic characteristics (pT stage, grade, lymphovascular invasion, pN stage, number of nodes removed, margin status). The median follow-up was 32 mo. RESULTS AND LIMITATIONS: The 5-yr CSS and OS rates were 67.7% and 57.5%, respectively. Given a 1-, 2-, 3-, 5- and 10-yr survivorship, the 5-yr conditional OS rates improved by +5.6 (60.7%), +8.4 (65.8%), +7.6 (70.8%), +3.0 (72.9%), and +1.9% (74.3%), respectively. The 5-yr conditional CSS rates improved by +5.6 (71.5%), +9.8 (78.5%), +7.9 (84.7%), +7.2 (90.8%), and 5.6% (95.9%), respectively. The 5- and 10-yr CS improvement was primarily noted among surviving patients with advanced stage disease. The impact of pathologic parameters on CS estimates decreased over time for both CSS and OS. Findings were confirmed on multivariable analyses. The main limitation was the retrospective design. CONCLUSIONS: CS analysis demonstrates that the patient risk profile changes over time. The risk of mortality decreases with increasing survivorship. The CS rates improve mainly in the case of advanced stage disease. The impact of prognostic pathologic features decreases over time and can disappear for long-term CS.
BACKGROUND: Standard survival statistics do not take into consideration the changes in the weight of individual variables at subsequent times after the diagnosis and initial treatment of bladder cancer. OBJECTIVE: To assess the changes in 5-yr conditional survival (CS) rates after radical cystectomy for bladder cancer and to determine how well-established prognostic factors evolve over time. DESIGN, SETTING, AND PARTICIPANTS: We analyzed data from 8141 patients treated with radical cystectomy at 15 international academic centers between 1979 and 2012. INTERVENTIONS: Radical cystectomy and pelvic lymph node dissection. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Conditional cancer-specific survival (CSS) and overall survival (OS) estimates were calculated using the Kaplan-Meier method. The multivariable Cox regression model was used to calculate proportional hazard ratios for the prediction of mortality after stratification by clinical characteristics (age, perioperative chemotherapy status) and pathologic characteristics (pT stage, grade, lymphovascular invasion, pN stage, number of nodes removed, margin status). The median follow-up was 32 mo. RESULTS AND LIMITATIONS: The 5-yr CSS and OS rates were 67.7% and 57.5%, respectively. Given a 1-, 2-, 3-, 5- and 10-yr survivorship, the 5-yr conditional OS rates improved by +5.6 (60.7%), +8.4 (65.8%), +7.6 (70.8%), +3.0 (72.9%), and +1.9% (74.3%), respectively. The 5-yr conditional CSS rates improved by +5.6 (71.5%), +9.8 (78.5%), +7.9 (84.7%), +7.2 (90.8%), and 5.6% (95.9%), respectively. The 5- and 10-yr CS improvement was primarily noted among surviving patients with advanced stage disease. The impact of pathologic parameters on CS estimates decreased over time for both CSS and OS. Findings were confirmed on multivariable analyses. The main limitation was the retrospective design. CONCLUSIONS:CS analysis demonstrates that the patient risk profile changes over time. The risk of mortality decreases with increasing survivorship. The CS rates improve mainly in the case of advanced stage disease. The impact of prognostic pathologic features decreases over time and can disappear for long-term CS.
Authors: Gianluca Ferini; Alberto Cacciola; Silvana Parisi; Sara Lillo; Laura Molino; Consuelo Tamburella; Valerio Davi; Ilenia Napoli; Angelo Platania; Nicola Settineri; Giuseppe Iati; Antonio Pontoriero; Stefano Pergolizzi; Anna Santacaterina Journal: In Vivo Date: 2021 Jan-Feb Impact factor: 2.155
Authors: Kim E M van Kessel; Tahlita C M Zuiverloon; Arnout R Alberts; Joost L Boormans; Ellen C Zwarthoff Journal: Nat Rev Urol Date: 2015-09-22 Impact factor: 14.432
Authors: Yuhree Kim; Georgios A Margonis; Jason D Prescott; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Jason A Glenn; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik Journal: Ann Surg Date: 2017-01 Impact factor: 12.969
Authors: Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens Journal: Can Urol Assoc J Date: 2016-02-08 Impact factor: 1.862
Authors: Sumanta Kumar Pal; Yulan Ingrid Lin; Bertram Yuh; Kara DeWalt; Austin Kazarian; Nicholas Vogelzang; Rebecca A Nelson Journal: PLoS One Date: 2015-08-26 Impact factor: 3.240